Drug Profile
ZD 2138
Alternative Names: ICI D 2138Latest Information Update: 21 Jan 2008
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Pyrans; Quinolones
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Rheumatoid arthritis
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 25 Mar 1999 No-Development-Reported for Asthma in Japan (PO)
- 25 Mar 1999 No-Development-Reported for Rheumatoid arthritis in Japan (PO)